Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high‐definition picture?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high‐definition picture?

Published:2021-04 Issue:2 Volume:11 Page:1-3
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Piccari Lucilla¹^ORCID,Bernardo Roberto J.²^ORCID,Rodríguez‐Chiaradía Diego¹³⁴,Vitulo Patrizio⁵⁶,Wort S. John⁷,Sahay Sandeep⁸⁹^ORCID

Affiliation:

1. Department of Pulmonary MedicineHospital del MarBarcelonaSpain

2. Division of PulmonaryCritical Care and Sleep MedicineUniversity of Oklahoma Health Sciences CenterOklahoma CityOKUSA

3. Biomedical Research Networking Centre on Respiratory Diseases (CIBERES)MadridSpain

4. University Pompeu FabraBarcelonaSpain

5. Department of Pulmonary MedicineIRCCS Istituto Mediterraneo Trapianti e Terapie ad Alta SpecializzazionePalermoItaly

6. Italian Pulmonary Hypertension NetworkIPHNETRomeItaly

7. Department of Pulmonary MedicineNational Pulmonary Hypertension ServiceRoyal Brompton HospitalLondonUK

8. Weill Cornell MedicineNew YorkNYUSA

9. Division of Pulmonary Critical Care and Sleep MedicineHouston Methodist HospitalHoustonTXUSA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/20458940211018074

Reference17 articles.

1. GillmeyerK MillerDR GlickmanME et al. Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease.Pulm Circ. Epub ahead of print 2021. DOI: 10.1177/20458940211001714.

2. Haemodynamic definitions and updated clinical classification of pulmonary hypertension;Simonneau G;Eur Respir J,2019

3. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial;Hoendermis ES;Eur Heart J,2015

4. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia;Corte TJ;Am J Respir Crit Care Med,2014

5. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial;Blanco I;Eur Respir J,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3